Beam Therapeutics Inc.
BEAMHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Beam Therapeutics Inc. (BEAM) is listed under Biotechnology. With a market capitalization of $3.28B, it sits in mid-cap territory. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Market Cap
$3.28B
Beta
2.26
P/E (TTM)
—
P/E (Fwd)
-6.72
EPS (TTM)
$-0.49
EPS (Fwd)
$-4.74
ROE
-5.8%
ROA
-15.8%
Cash
$1.21B
Total Debt
$250.8M
Free CF
-$233.6M
52W Change
95.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $1.21B in cash comfortably exceeding the $250.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$233.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -5.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $60.9M (2022) to $139.7M (2025), reflecting a 129% increase over the period.
Beam Therapeutics Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BEAM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.